JP6616688B2 - 甲状腺ホルモンアナログ及びその多形体の合成方法 - Google Patents

甲状腺ホルモンアナログ及びその多形体の合成方法 Download PDF

Info

Publication number
JP6616688B2
JP6616688B2 JP2015532148A JP2015532148A JP6616688B2 JP 6616688 B2 JP6616688 B2 JP 6616688B2 JP 2015532148 A JP2015532148 A JP 2015532148A JP 2015532148 A JP2015532148 A JP 2015532148A JP 6616688 B2 JP6616688 B2 JP 6616688B2
Authority
JP
Japan
Prior art keywords
compound
batch
acid
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015532148A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535817A5 (enExample
JP2015535817A (ja
Inventor
ヘスター，ディー・キース
ダギッド，ロバート・ジェイ
ケリー，マーサ
シャスノフ，アンナ
ドン，ガン
クロウ，エドウィン・エル
タウブ，レベッカ
レイノルズ，チャールズ・エイチ
チェ，ドク・スン
シュウ，リエンホー
ワン，ピン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Madrigal Pharmaceuticals Inc
Original Assignee
F Hoffmann La Roche AG
Madrigal Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50278769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6616688(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG, Madrigal Pharmaceuticals Inc filed Critical F Hoffmann La Roche AG
Publication of JP2015535817A publication Critical patent/JP2015535817A/ja
Publication of JP2015535817A5 publication Critical patent/JP2015535817A5/ja
Priority to JP2019154299A priority Critical patent/JP6899413B2/ja
Application granted granted Critical
Publication of JP6616688B2 publication Critical patent/JP6616688B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
JP2015532148A 2012-09-17 2013-09-17 甲状腺ホルモンアナログ及びその多形体の合成方法 Active JP6616688B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019154299A JP6899413B2 (ja) 2012-09-17 2019-08-27 甲状腺ホルモンアナログ及びその多形体の合成方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261702137P 2012-09-17 2012-09-17
US61/702,137 2012-09-17
US201361790432P 2013-03-15 2013-03-15
US61/790,432 2013-03-15
PCT/US2013/060177 WO2014043706A1 (en) 2012-09-17 2013-09-17 Method of synthesizing thyroid hormone analogs and polymorphs thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2017249107A Division JP6532931B2 (ja) 2012-09-17 2017-12-26 甲状腺ホルモンアナログ及びその多形体の合成方法
JP2019154299A Division JP6899413B2 (ja) 2012-09-17 2019-08-27 甲状腺ホルモンアナログ及びその多形体の合成方法

Publications (3)

Publication Number Publication Date
JP2015535817A JP2015535817A (ja) 2015-12-17
JP2015535817A5 JP2015535817A5 (enExample) 2016-11-04
JP6616688B2 true JP6616688B2 (ja) 2019-12-04

Family

ID=50278769

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2015532148A Active JP6616688B2 (ja) 2012-09-17 2013-09-17 甲状腺ホルモンアナログ及びその多形体の合成方法
JP2017249107A Active JP6532931B2 (ja) 2012-09-17 2017-12-26 甲状腺ホルモンアナログ及びその多形体の合成方法
JP2018217045A Active JP6765408B2 (ja) 2012-09-17 2018-11-20 甲状腺ホルモンアナログ及びその多形体の合成方法
JP2019154299A Active JP6899413B2 (ja) 2012-09-17 2019-08-27 甲状腺ホルモンアナログ及びその多形体の合成方法
JP2020020343A Active JP7038745B2 (ja) 2012-09-17 2020-02-10 甲状腺ホルモンアナログ及びその多形体の合成方法
JP2022034154A Active JP7436542B2 (ja) 2012-09-17 2022-03-07 甲状腺ホルモンアナログ及びその多形体の合成方法
JP2024016915A Pending JP2024056793A (ja) 2012-09-17 2024-02-07 甲状腺ホルモンアナログ及びその多形体の合成方法
JP2025145966A Pending JP2025179154A (ja) 2012-09-17 2025-09-03 甲状腺ホルモンアナログ及びその多形体の合成方法

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2017249107A Active JP6532931B2 (ja) 2012-09-17 2017-12-26 甲状腺ホルモンアナログ及びその多形体の合成方法
JP2018217045A Active JP6765408B2 (ja) 2012-09-17 2018-11-20 甲状腺ホルモンアナログ及びその多形体の合成方法
JP2019154299A Active JP6899413B2 (ja) 2012-09-17 2019-08-27 甲状腺ホルモンアナログ及びその多形体の合成方法
JP2020020343A Active JP7038745B2 (ja) 2012-09-17 2020-02-10 甲状腺ホルモンアナログ及びその多形体の合成方法
JP2022034154A Active JP7436542B2 (ja) 2012-09-17 2022-03-07 甲状腺ホルモンアナログ及びその多形体の合成方法
JP2024016915A Pending JP2024056793A (ja) 2012-09-17 2024-02-07 甲状腺ホルモンアナログ及びその多形体の合成方法
JP2025145966A Pending JP2025179154A (ja) 2012-09-17 2025-09-03 甲状腺ホルモンアナログ及びその多形体の合成方法

Country Status (32)

Country Link
US (8) US9266861B2 (enExample)
EP (5) EP4406594B1 (enExample)
JP (8) JP6616688B2 (enExample)
KR (4) KR101966490B1 (enExample)
CN (2) CN108101851A (enExample)
AR (1) AR092872A1 (enExample)
AU (1) AU2013315017C1 (enExample)
BR (2) BR122021024202B1 (enExample)
CA (3) CA2884481C (enExample)
DK (3) DK3689853T3 (enExample)
ES (3) ES2795450T3 (enExample)
FI (2) FI4406594T3 (enExample)
FR (1) FR26C1009I1 (enExample)
HR (1) HRP20251398T1 (enExample)
IL (7) IL314360B2 (enExample)
IN (1) IN2015DN03133A (enExample)
LT (2) LT4406594T (enExample)
MX (2) MX364661B (enExample)
MY (1) MY170520A (enExample)
NL (1) NL301369I2 (enExample)
NO (1) NO2026010I1 (enExample)
NZ (2) NZ705827A (enExample)
PL (1) PL4406594T3 (enExample)
PT (1) PT4406594T (enExample)
RS (1) RS67728B1 (enExample)
RU (2) RU2018128393A (enExample)
SG (3) SG10201705984XA (enExample)
SI (1) SI4406594T1 (enExample)
SM (1) SMT202500439T1 (enExample)
TW (4) TWI755628B (enExample)
WO (1) WO2014043706A1 (enExample)
ZA (1) ZA201501795B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020109090A (ja) * 2012-09-17 2020-07-16 マドリガル・ファーマシューティカルズ・インコーポレーテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 甲状腺ホルモンアナログ及びその多形体の合成方法

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394463B (es) * 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
CN109574995B (zh) * 2018-01-23 2020-07-24 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
ES3029158T3 (en) 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
US20210292304A1 (en) * 2018-06-22 2021-09-23 Hinova Pharmaceuticals Inc. Deuterated mgl-3196 compound and use thereof
TW202615431A (zh) * 2018-07-02 2026-04-16 美商瑪德瑞高製藥公司 ２－（３，５－二氯－４－（（５－異丙基－６－側氧基－１，６－二氫噠嗪－３－基）氧）苯基）－３，５－二側氧基－２，３，４，５－四氫－１，２，４－三嗪－６－腈之固體型式
CN119552152A (zh) * 2018-10-12 2025-03-04 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN119431265A (zh) 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
WO2020227549A1 (en) * 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
WO2020228577A1 (zh) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2020239076A1 (zh) * 2019-05-29 2020-12-03 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN112442013B (zh) * 2019-09-04 2022-07-26 广东东阳光药业有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021063367A1 (zh) * 2019-09-30 2021-04-08 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CN112707892A (zh) * 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
CA3158379A1 (en) * 2019-11-26 2021-06-03 Hejun Lv 1,2,4-triazine-3,5-dione compound, preparation method therefor, and application thereof
WO2021121210A1 (zh) * 2019-12-16 2021-06-24 江苏恒瑞医药股份有限公司 并环类衍生物、其制备方法及其在医药上的应用
WO2021129465A1 (zh) * 2019-12-26 2021-07-01 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
WO2022041026A1 (en) * 2020-08-27 2022-03-03 InventisBio Co., Ltd. Pyridazinone compounds
KR20230066408A (ko) * 2020-09-10 2023-05-15 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 레스메티롬의 결정형, 이의 제조 방법 및 이의 용도
US12616701B2 (en) 2020-10-19 2026-05-05 Assia Chemical Industries Ltd Solid state forms of Resmetirom
CN114437042A (zh) * 2020-11-03 2022-05-06 深圳微芯生物科技股份有限公司 酞嗪类化合物的晶型及其制备方法
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法
WO2022165227A1 (en) 2021-02-01 2022-08-04 Madrigal Pharmaceuticals, Inc. Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
TW202337470A (zh) 2021-09-27 2023-10-01 美商瑪德瑞高製藥公司 用於縮減肝臟體積之瑞美替隆
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
CN116768802B (zh) * 2023-05-25 2025-11-21 杭州科巢生物科技有限公司 一种瑞司美替罗的合成方法
JP2026521649A (ja) 2023-06-22 2026-06-30 マドリガル ファーマシューティカルズ インコーポレイテッド ＴＨＲ－βアゴニストを用いて肝障害を治療するためのバイオマーカーおよび関連する使用
CN119613386A (zh) * 2023-09-14 2025-03-14 杭州科巢生物科技有限公司 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法
CN117263870B (zh) * 2023-09-21 2026-02-06 江西同和药业股份有限公司 一种Resmetirom关键中间体III的制备方法
EP4762048A2 (en) 2023-10-16 2026-06-24 Cipla Limited Resmetirom polymorphs and process for their preparation
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
AU2024408289A1 (en) 2023-12-22 2026-08-06 Tangram Therapeutics Plc Inhibitors of expression and/or function
WO2025164161A1 (ja) * 2024-01-29 2025-08-07 シオノギファーマ株式会社 カンナビジオールの溶媒和物及びカンナビジオールの精製方法
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025171032A1 (en) 2024-02-06 2025-08-14 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025191457A1 (en) * 2024-03-13 2025-09-18 Morepen Laboratories Limited Process for the preparation of pyridazinone derivative
CN119019375A (zh) * 2024-08-14 2024-11-26 奥锐特药业(天津)有限公司 一种瑞司美替罗新晶型及其制备方法
WO2026067708A1 (zh) * 2024-09-30 2026-04-02 齐鲁制药有限公司 瑞司美替罗晶型及其制备方法和用途
WO2026074443A1 (en) 2024-10-01 2026-04-09 Assia Chemical Industries Ltd. Solid state forms of resmetirom
CN119306670A (zh) * 2024-10-12 2025-01-14 北京海美桐医药科技有限公司 瑞司美替罗中间体、其合成方法和瑞司美替罗的合成方法
WO2026107045A1 (en) 2024-11-12 2026-05-21 Madrigal Pharmaceuticals, Inc. Resmetirom for use in treating cardiomyopathy and/or related heart failure and portal hypertension

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5615272A (en) * 1979-07-17 1981-02-14 Ishihara Sangyo Kaisha Ltd N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
RU2346950C2 (ru) 2003-01-28 2009-02-20 Академис Зикенхейс Лейден Пептидные ингибиторы токсинов, производные ll-37
WO2004085406A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
ITRM20030363A1 (it) 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
US7807647B2 (en) * 2004-06-01 2010-10-05 Pronai Therapeutics, Inc. Methods and compositions for cancer therapy
US20050287667A1 (en) 2004-06-01 2005-12-29 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
BRPI0517947A (pt) 2004-11-02 2008-10-21 Univ Northwestern composto de piridazina, composições e métodos
JPWO2007000913A1 (ja) 2005-06-27 2009-01-22 国立大学法人東京工業大学 高級脂肪酸エステルの製造方法
ATE480524T1 (de) 2005-07-21 2010-09-15 Hoffmann La Roche Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
ES2351274T3 (es) * 2007-06-06 2011-02-02 Torrent Pharmaceuticals Ltd Nuevos compuestos.
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
ES2795450T3 (es) 2012-09-17 2020-11-23 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
US8858502B2 (en) 2012-10-10 2014-10-14 Alcon Research, Ltd. Systems and methods for external pressure sensing
WO2015123256A1 (en) 2014-02-14 2015-08-20 Cempra Pharmaceuticals, Inc. Compositions and methods for treating diabetes and liver diseases
MX394463B (es) 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
ES3029158T3 (en) 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
TW202615431A (zh) 2018-07-02 2026-04-16 美商瑪德瑞高製藥公司 ２－（３，５－二氯－４－（（５－異丙基－６－側氧基－１，６－二氫噠嗪－３－基）氧）苯基）－３，５－二側氧基－２，３，４，５－四氫－１，２，４－三嗪－６－腈之固體型式
CN119552152A (zh) 2018-10-12 2025-03-04 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020109090A (ja) * 2012-09-17 2020-07-16 マドリガル・ファーマシューティカルズ・インコーポレーテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 甲状腺ホルモンアナログ及びその多形体の合成方法
JP7038745B2 (ja) 2012-09-17 2022-03-18 マドリガル・ファーマシューティカルズ・インコーポレーテッド 甲状腺ホルモンアナログ及びその多形体の合成方法

Also Published As

Publication number Publication date
JP2019048856A (ja) 2019-03-28
MX2015003418A (es) 2016-04-04
HK1212682A1 (en) 2016-06-17
AU2013315017A1 (en) 2015-04-02
DK3689853T3 (da) 2022-03-07
US9266861B2 (en) 2016-02-23
KR20200023528A (ko) 2020-03-04
EP2895466B1 (en) 2020-03-25
US10376517B2 (en) 2019-08-13
US20230210856A1 (en) 2023-07-06
TW201906835A (zh) 2019-02-16
WO2014043706A8 (en) 2017-10-19
FI4406594T3 (fi) 2025-11-26
US11986481B2 (en) 2024-05-21
CN105008335B (zh) 2018-12-21
TW201946917A (zh) 2019-12-16
FR26C1009I1 (fr) 2026-04-17
SMT202500439T1 (it) 2026-05-12
BR112015005891A2 (pt) 2017-08-08
IL259610B (en) 2020-06-30
CA3090070C (en) 2023-01-24
JP6899413B2 (ja) 2021-07-07
KR102138750B1 (ko) 2020-07-29
KR102363776B1 (ko) 2022-02-15
AU2013315017B2 (en) 2017-07-27
JP2024056793A (ja) 2024-04-23
CA3111317C (en) 2023-08-29
JP2022078218A (ja) 2022-05-24
JP6532931B2 (ja) 2019-06-19
EP4406594A3 (en) 2024-11-06
SG10202006058QA (en) 2020-08-28
HRP20251398T1 (hr) 2026-03-13
EP4406594A2 (en) 2024-07-31
FIC20265007I1 (fi) 2026-03-03
EP4406594B1 (en) 2025-09-10
JP2020015739A (ja) 2020-01-30
IL237628A0 (en) 2015-04-30
NO2026010I1 (no) 2026-03-03
RU2668960C2 (ru) 2018-10-05
MX395148B (es) 2025-03-24
EP4691557A3 (en) 2026-03-18
JP2020109090A (ja) 2020-07-16
WO2014043706A1 (en) 2014-03-20
PL4406594T3 (pl) 2026-03-30
SG11201501907YA (en) 2015-04-29
KR20180131647A (ko) 2018-12-10
IL265030B (en) 2020-07-30
IL320269A (en) 2025-06-01
NZ705827A (en) 2018-07-27
IL237628B (en) 2019-07-31
KR20210083381A (ko) 2021-07-06
AR092872A1 (es) 2015-05-06
JP2015535817A (ja) 2015-12-17
TWI804870B (zh) 2023-06-11
MX2018014924A (es) 2020-09-02
US20240148742A1 (en) 2024-05-09
US20190381053A1 (en) 2019-12-19
EP2895466A1 (en) 2015-07-22
TW202134217A (zh) 2021-09-16
PT4406594T (pt) 2025-11-28
IL288133B2 (en) 2024-12-01
IL314360A (en) 2024-09-01
JP7038745B2 (ja) 2022-03-18
KR101966490B1 (ko) 2019-08-14
US20210161904A1 (en) 2021-06-03
SG10201705984XA (en) 2017-08-30
ZA201501795B (en) 2021-10-27
IL288133A (en) 2022-01-01
US20180228807A1 (en) 2018-08-16
JP6765408B2 (ja) 2020-10-07
EP4023641B1 (en) 2024-05-01
CN105008335A (zh) 2015-10-28
SI4406594T1 (sl) 2026-03-31
IL275393B (en) 2022-01-01
US20160243126A1 (en) 2016-08-25
JP2025179154A (ja) 2025-12-09
US9968612B2 (en) 2018-05-15
ES3053122T3 (en) 2026-01-19
KR20150056630A (ko) 2015-05-26
IL259610A (en) 2018-07-31
TW201425300A (zh) 2014-07-01
CA3090070A1 (en) 2014-03-20
IL288133B1 (en) 2024-08-01
LTPA2026507I1 (enExample) 2026-03-10
TWI681957B (zh) 2020-01-11
IL275393A (en) 2020-07-30
EP3689853B1 (en) 2021-11-24
EP4691557A2 (en) 2026-02-11
US10894050B2 (en) 2021-01-19
BR122021024202B1 (pt) 2022-05-17
IL314360B1 (en) 2025-05-01
CA2884481A1 (en) 2014-03-20
RU2018128393A3 (enExample) 2019-04-16
DK2895466T3 (da) 2020-06-08
RU2015114327A (ru) 2016-11-10
MX364661B (es) 2019-05-03
CA3111317A1 (en) 2014-03-20
EP2895466A4 (en) 2016-08-10
AU2013315017C1 (en) 2017-11-23
TWI652260B (zh) 2019-03-01
EP4023641A2 (en) 2022-07-06
US11564926B2 (en) 2023-01-31
ES2795450T3 (es) 2020-11-23
RU2018128393A (ru) 2019-03-14
IN2015DN03133A (enExample) 2015-10-02
US20150203473A1 (en) 2015-07-23
ES2907926T3 (es) 2022-04-27
CA2884481C (en) 2021-04-27
TWI755628B (zh) 2022-02-21
NZ739645A (en) 2019-11-29
LT4406594T (lt) 2025-12-29
CN108101851A (zh) 2018-06-01
EP3689853A1 (en) 2020-08-05
US20240122936A1 (en) 2024-04-18
EP4023641A3 (en) 2022-09-14
RS67728B1 (sr) 2026-03-31
MY170520A (en) 2019-08-08
JP2018080188A (ja) 2018-05-24
NL301369I2 (nl) 2026-03-30
IL314360B2 (en) 2025-09-01
JP7436542B2 (ja) 2024-02-21
DK4406594T3 (da) 2025-11-03

Similar Documents

Publication Publication Date Title
US11986481B2 (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
HK40113302B (en) Thyroid hormone analogs
HK40113302A (en) Thyroid hormone analogs
HK40077432B (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
HK1212682B (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170627

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190827

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191108

R150 Certificate of patent or registration of utility model

Ref document number: 6616688

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250